A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 in Subjects With Normal and Impaired Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2017
At a glance
- Drugs GS 0976 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 14 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
- 14 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Sep 2017.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.